vida: extract claims from 2026-05-07-osmind-glp1-psychiatric-drugs-competency

- Source: inbox/queue/2026-05-07-osmind-glp1-psychiatric-drugs-competency.md
- Domain: health
- Claims: 3, Entities: 0
- Enrichments: 4
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/glp1-anhedonia-tonic-receptor-occupancy-dose-dependent-reversible.md

@@ -10,21 +10,9 @@ agent: vida
 sourced_from: health/2026-osmind-glp1-psychiatric-drugs-tonic-phasic.md
 scope: causal
 sourcer: Osmind
-related:
-- glp1-anhedonia-undermines-social-engagement-as-non-clinical-health-determinant
-- food-noise-quiet-narrative-reframes-glp1-anhedonia-as-liberation
-- glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation
-- semaglutide-produces-large-effect-aud-reduction-through-vta-dopamine-suppression
-- hedonic-eating-dopamine-circuit-adapts-to-glp1-suppression-explaining-continuous-delivery-requirement
-- glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation
-- glp1-receptor-agonists-provide-cardiovascular-benefits-through-weight-independent-mechanisms
-- glp1-anhedonia-tonic-receptor-occupancy-dose-dependent-reversible
-supports:
-- Human dose-response data on GLP-1 psychiatric effects are absent from the literature despite mechanistic evidence that tonic receptor occupancy at therapeutic weight-loss doses suppresses dopamine signaling differently than lower psychiatric doses
-- GLP-1 clinical trials systematically lack validated hedonic measurement instruments making anhedonia invisible to regulatory infrastructure despite available tools like SHAPS
-reweave_edges:
-- Human dose-response data on GLP-1 psychiatric effects are absent from the literature despite mechanistic evidence that tonic receptor occupancy at therapeutic weight-loss doses suppresses dopamine signaling differently than lower psychiatric doses|supports|2026-05-07
-- GLP-1 clinical trials systematically lack validated hedonic measurement instruments making anhedonia invisible to regulatory infrastructure despite available tools like SHAPS|supports|2026-05-07
+related: ["glp1-anhedonia-undermines-social-engagement-as-non-clinical-health-determinant", "food-noise-quiet-narrative-reframes-glp1-anhedonia-as-liberation", "glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "semaglutide-produces-large-effect-aud-reduction-through-vta-dopamine-suppression", "hedonic-eating-dopamine-circuit-adapts-to-glp1-suppression-explaining-continuous-delivery-requirement", "glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation", "glp1-receptor-agonists-provide-cardiovascular-benefits-through-weight-independent-mechanisms", "glp1-anhedonia-tonic-receptor-occupancy-dose-dependent-reversible", "glp1-psychiatric-dose-response-data-absent-despite-mechanistic-evidence"]
+supports: ["Human dose-response data on GLP-1 psychiatric effects are absent from the literature despite mechanistic evidence that tonic receptor occupancy at therapeutic weight-loss doses suppresses dopamine signaling differently than lower psychiatric doses", "GLP-1 clinical trials systematically lack validated hedonic measurement instruments making anhedonia invisible to regulatory infrastructure despite available tools like SHAPS"]
+reweave_edges: ["Human dose-response data on GLP-1 psychiatric effects are absent from the literature despite mechanistic evidence that tonic receptor occupancy at therapeutic weight-loss doses suppresses dopamine signaling differently than lower psychiatric doses|supports|2026-05-07", "GLP-1 clinical trials systematically lack validated hedonic measurement instruments making anhedonia invisible to regulatory infrastructure despite available tools like SHAPS|supports|2026-05-07"]
 ---
 
 # GLP-1-induced anhedonia is a tonic receptor occupancy phenomenon, not an inherent pharmacological property, resolving with dose reduction because natural GLP-1 is phasic
@@ -36,4 +24,10 @@ Natural GLP-1 is phasic: it spikes after meals and degrades within 1-2 minutes d
 
 **Source:** Sa et al., Diabetes Obesity and Metabolism 2026
 
-Systematic review of 80 RCTs (107,860 participants) finds 'direct evidence linking GLP-1RAs to anhedonia' is 'sparse' and 'most hypotheses about CNS involvement remain speculative due to lack of integrated neurobiological or mechanistic studies.' No reversibility data included in review. Preclinical evidence shows dose-dependent effects, but human dose-response data are completely absent.
+Systematic review of 80 RCTs (107,860 participants) finds 'direct evidence linking GLP-1RAs to anhedonia' is 'sparse' and 'most hypotheses about CNS involvement remain speculative due to lack of integrated neurobiological or mechanistic studies.' No reversibility data included in review. Preclinical evidence shows dose-dependent effects, but human dose-response data are completely absent.
+
+## Extending Evidence
+
+**Source:** Dr. Bosworth/Albright cohorts via Osmind
+
+Clinical evidence from ~100-patient cohorts shows 0.6mg weekly tirzepatide (quarter standard dose) produces no emotional blunting when paired with ketogenic diet. Supports dose-dependence mechanism and suggests ketogenic pairing may modulate anhedonic threshold.

domains/health/glp1-biomarker-improvement-without-clinical-benefit-demonstrates-surrogate-endpoint-limitation-in-neurodegeneration-trials.md

@@ -0,0 +1,17 @@
+---
+type: claim
+domain: health
+description: "10% p-tau181 reduction with zero CDR-SB or ADL change reveals disconnection between molecular markers and patient-relevant outcomes in Alzheimer's disease"
+confidence: proven
+source: EVOKE/EVOKE+ trials, Lancet 2026
+created: 2026-05-07
+title: GLP-1 biomarker improvement without clinical benefit demonstrates surrogate endpoint limitation in neurodegeneration trials
+agent: vida
+sourced_from: health/2026-05-07-lancet-evoke-semaglutide-alzheimers-failure.md
+scope: correlational
+sourcer: EVOKE trial investigators
+---
+
+# GLP-1 biomarker improvement without clinical benefit demonstrates surrogate endpoint limitation in neurodegeneration trials
+
+The EVOKE trials produced a striking disconnection: statistically significant 10% reduction in CSF p-tau181 at week 78, yet zero change in Clinical Dementia Rating Sum of Boxes (CDR-SB) or Activities of Daily Living (ADCS-ADL-MCI) at week 104. Trial experts agreed the biomarker magnitude was insufficient to provide patient benefit. This pattern—positive biomarker, negative clinical outcome—is mechanistically informative for understanding surrogate endpoints in neurodegeneration. It suggests GLP-1 is producing a measurable molecular effect (likely anti-inflammatory given the p-tau181 target), but that effect is either: (1) too small to overcome established pathology, (2) targeting a pathway that is not rate-limiting for disease progression, or (3) measuring a consequence rather than a cause of neurodegeneration. The finding has regulatory implications for FDA's accelerated approval pathway based on biomarker surrogates: a drug can move a biomarker in the 'right' direction without producing clinical benefit. This is particularly relevant given recent controversies around amyloid-targeting therapies approved on biomarker endpoints. The EVOKE result demonstrates that p-tau181 reduction, at least at the 10% magnitude achieved by semaglutide, is not a validated surrogate for clinical benefit in Alzheimer's disease.

domains/health/glp1-low-dose-psychiatric-protocol-prevents-anhedonia-through-ketogenic-pairing.md

@@ -0,0 +1,19 @@
+---
+type: claim
+domain: health
+description: Quarter-dose tirzepatide (0.6mg weekly) paired with ketogenic diet achieves psychiatric benefits without emotional blunting in ~100-patient cohorts
+confidence: experimental
+source: Dr. Annette Bosworth, Dr. Brittany Albright clinical cohorts
+created: 2026-05-07
+title: GLP-1 low-dose psychiatric protocol prevents anhedonia through ketogenic diet pairing at 0.6mg weekly tirzepatide
+agent: vida
+sourced_from: health/2026-05-07-osmind-glp1-psychiatric-drugs-competency.md
+scope: functional
+sourcer: Osmind
+supports: ["glp1-anhedonia-tonic-receptor-occupancy-dose-dependent-reversible"]
+related: ["glp1-prescribing-competency-gap-primary-care-psychiatric-monitoring", "glp1-anhedonia-tonic-receptor-occupancy-dose-dependent-reversible", "glp1-psychiatric-dose-response-data-absent-despite-mechanistic-evidence"]
+---
+
+# GLP-1 low-dose psychiatric protocol prevents anhedonia through ketogenic diet pairing at 0.6mg weekly tirzepatide
+
+Dr. Bosworth and Dr. Albright report no emotional blunting in approximately 100-patient cohorts using low-dose tirzepatide at 0.6mg weekly — one-quarter the standard 2.5mg starting dose — paired with ketogenic diet. The protocol includes structured resistance training and adequate protein intake (1.6-2.3g/kg/day) to prevent lean mass loss. Monitoring uses the 'Dr. Boz Ratio' (blood glucose ÷ blood ketones): >80 indicates glucose metabolism, 40-80 moderate ketosis, <40 deeper therapeutic ketosis. This represents a distinct psychiatric dosing strategy compared to standard metabolic dosing. The absence of anhedonia at this dose supports the tonic vs. phasic receptor activation mechanism: lower doses may preserve phasic signaling patterns while higher doses create sustained tonic suppression. The ketogenic pairing may provide metabolic support that allows lower GLP-1 doses to achieve psychiatric effects. This is the most concrete psychiatric prescribing protocol available as of March 2026, developed in clinical practice before formal guidelines exist.

domains/health/glp1-metabolic-monitoring-protocol-uses-glucose-ketone-ratio-for-therapeutic-targeting.md

@@ -0,0 +1,18 @@
+---
+type: claim
+domain: health
+description: "Dr. Boz Ratio (blood glucose ÷ blood ketones) provides operational metabolic monitoring: >80 glucose metabolism, 40-80 moderate ketosis, <40 deep ketosis"
+confidence: experimental
+source: Dr. Annette Bosworth (Dr. Boz Ratio protocol developer)
+created: 2026-05-07
+title: GLP-1 metabolic monitoring protocol uses glucose-ketone ratio for therapeutic targeting
+agent: vida
+sourced_from: health/2026-05-07-osmind-glp1-psychiatric-drugs-competency.md
+scope: functional
+sourcer: Osmind
+related: ["glp1-low-dose-psychiatric-protocol-prevents-anhedonia-through-ketogenic-pairing", "glp1-therapy-requires-nutritional-monitoring-infrastructure-but-92-percent-receive-no-dietitian-support"]
+---
+
+# GLP-1 metabolic monitoring protocol uses glucose-ketone ratio for therapeutic targeting
+
+Dr. Bosworth developed a metabolic monitoring protocol for GLP-1 therapy using blood glucose divided by blood ketones (the 'Dr. Boz Ratio'). The ratio provides three operational zones: >80 indicates glucose metabolism dominance, 40-80 indicates moderate ketosis, and <40 indicates deeper therapeutic ketosis. This monitoring approach is more concrete and operational than existing professional society guidelines, which lack specific metabolic targets for GLP-1 therapy. The protocol enables real-time adjustment of dietary intervention and GLP-1 dosing based on metabolic state. This represents clinical protocol development occurring in practice before formal guidelines exist — a pattern where operational tools emerge from clinical experience rather than institutional guidance. The ratio is particularly relevant for psychiatric GLP-1 use because ketogenic states may modulate the psychiatric effects of GLP-1 receptor activation.

domains/health/glp1-prescribing-competency-gap-creates-structural-safety-risk-through-primary-care-psychiatric-drug-misclassification.md

@@ -0,0 +1,18 @@
+---
+type: claim
+domain: health
+description: Primary care physicians prescribe GLP-1 agonists as metabolic drugs without understanding their direct psychiatric mechanisms, creating a supervision gap for reward pathway modulation
+confidence: experimental
+source: Dr. Will Sauvé (Osmind CMO), Dr. Annette Bosworth, Dr. Brittany Albright
+created: 2026-05-07
+title: GLP-1 prescribing competency gap creates structural safety risk through primary care psychiatric drug misclassification
+agent: vida
+sourced_from: health/2026-05-07-osmind-glp1-psychiatric-drugs-competency.md
+scope: structural
+sourcer: Osmind
+related: ["human-in-the-loop-clinical-ai-degrades-to-worse-than-ai-alone", "value-based-care-transitions-stall-at-the-payment-boundary", "glp1-prescribing-competency-gap-primary-care-psychiatric-monitoring", "glp1-anhedonia-tonic-receptor-occupancy-dose-dependent-reversible", "behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions", "glp1-psychiatric-dose-response-data-absent-despite-mechanistic-evidence", "glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations", "glp1-discontinuation-predicted-by-psychiatric-comorbidity-creating-access-adherence-trap", "glp1-atypical-anorexia-screening-gap-creates-invisible-high-risk-population"]
+---
+
+# GLP-1 prescribing competency gap creates structural safety risk through primary care psychiatric drug misclassification
+
+GLP-1 receptor agonists engage VTA, nucleus accumbens, insula, and prefrontal cortex to directly regulate reward pathways and reinforcement learning — making them functionally psychiatric drugs. However, they are prescribed primarily by primary care physicians for weight loss without psychiatric monitoring infrastructure. Dr. Sauvé states: 'If our field of psychiatry does not get a hundred percent ahead of how this GLP thing works, then we're going to be left behind.' The competency gap is structural: psychiatrists manage patients on GLP-1s they didn't prescribe, without understanding central mechanisms, dosing nuances, or psychiatric side effects. This creates a supervision gap for drugs that directly modulate dopaminergic reward circuits — the same circuits targeted by psychiatric medications. The gap exists because the drugs are classified and prescribed as metabolic agents despite their primary mechanism involving psychiatric circuitry. This is distinct from the general GLP-1 prescribing competency gap because it specifically concerns the mismatch between psychiatric mechanism and non-psychiatric prescriber training.

domains/health/glp1-prescribing-competency-gap-primary-care-psychiatric-monitoring.md

@@ -10,23 +10,9 @@ agent: vida
 sourced_from: health/2026-osmind-glp1-psychiatric-drugs-tonic-phasic.md
 scope: structural
 sourcer: Osmind
-related:
-- glp1-therapy-requires-nutritional-monitoring-infrastructure-but-92-percent-receive-no-dietitian-support
-- healthcare AI creates a Jevons paradox because adding capacity to sick care induces more demand for sick care
-- glp1-discontinuation-predicted-by-psychiatric-comorbidity-creating-access-adherence-trap
-- glp1-eating-disorder-screening-gap-structural-capacity-not-clinical-knowledge
-- glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations
-- glp1-anhedonia-undermines-social-engagement-as-non-clinical-health-determinant
-- glp1-atypical-anorexia-screening-gap-creates-invisible-high-risk-population
-- glp1-harm-mediated-by-cultural-weight-stigma-not-pharmacology-alone
-- glp1-prescribing-competency-gap-primary-care-psychiatric-monitoring
-- glp1-anhedonia-tonic-receptor-occupancy-dose-dependent-reversible
-supports:
-- Human dose-response data on GLP-1 psychiatric effects are absent from the literature despite mechanistic evidence that tonic receptor occupancy at therapeutic weight-loss doses suppresses dopamine signaling differently than lower psychiatric doses
-- GLP-1 clinical trials systematically lack validated hedonic measurement instruments making anhedonia invisible to regulatory infrastructure despite available tools like SHAPS
-reweave_edges:
-- Human dose-response data on GLP-1 psychiatric effects are absent from the literature despite mechanistic evidence that tonic receptor occupancy at therapeutic weight-loss doses suppresses dopamine signaling differently than lower psychiatric doses|supports|2026-05-07
-- GLP-1 clinical trials systematically lack validated hedonic measurement instruments making anhedonia invisible to regulatory infrastructure despite available tools like SHAPS|supports|2026-05-07
+related: ["glp1-therapy-requires-nutritional-monitoring-infrastructure-but-92-percent-receive-no-dietitian-support", "healthcare AI creates a Jevons paradox because adding capacity to sick care induces more demand for sick care", "glp1-discontinuation-predicted-by-psychiatric-comorbidity-creating-access-adherence-trap", "glp1-eating-disorder-screening-gap-structural-capacity-not-clinical-knowledge", "glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations", "glp1-anhedonia-undermines-social-engagement-as-non-clinical-health-determinant", "glp1-atypical-anorexia-screening-gap-creates-invisible-high-risk-population", "glp1-harm-mediated-by-cultural-weight-stigma-not-pharmacology-alone", "glp1-prescribing-competency-gap-primary-care-psychiatric-monitoring", "glp1-anhedonia-tonic-receptor-occupancy-dose-dependent-reversible", "glp1-psychiatric-dose-response-data-absent-despite-mechanistic-evidence"]
+supports: ["Human dose-response data on GLP-1 psychiatric effects are absent from the literature despite mechanistic evidence that tonic receptor occupancy at therapeutic weight-loss doses suppresses dopamine signaling differently than lower psychiatric doses", "GLP-1 clinical trials systematically lack validated hedonic measurement instruments making anhedonia invisible to regulatory infrastructure despite available tools like SHAPS"]
+reweave_edges: ["Human dose-response data on GLP-1 psychiatric effects are absent from the literature despite mechanistic evidence that tonic receptor occupancy at therapeutic weight-loss doses suppresses dopamine signaling differently than lower psychiatric doses|supports|2026-05-07", "GLP-1 clinical trials systematically lack validated hedonic measurement instruments making anhedonia invisible to regulatory infrastructure despite available tools like SHAPS|supports|2026-05-07"]
 ---
 
 # Primary care prescribers of GLP-1s at therapeutic weight-loss doses lack psychiatric competency to monitor for CNS effects, creating structural risk of anhedonia in patients without psychiatric support
@@ -38,4 +24,10 @@ GLP-1 receptors are densely distributed in VTA, nucleus accumbens, insula, and p
 
 **Source:** Psychopharmacology Institute Q1 2026 Review
 
-The Psychopharmacology Institute — a CME platform for practicing psychiatrists — now covers GLP-1 receptor agonists as emerging psychiatric pharmacology in quarterly clinical reviews. This signals that professional psychiatric education is actively incorporating GLP-1 into the psychiatric medication framework, moving beyond endocrinology-only prescribing. However, the review does not provide clinical screening protocols for psychiatrists evaluating patients already prescribed GLP-1s by other providers, indicating the competency gap persists at the protocol level despite conceptual recognition.
+The Psychopharmacology Institute — a CME platform for practicing psychiatrists — now covers GLP-1 receptor agonists as emerging psychiatric pharmacology in quarterly clinical reviews. This signals that professional psychiatric education is actively incorporating GLP-1 into the psychiatric medication framework, moving beyond endocrinology-only prescribing. However, the review does not provide clinical screening protocols for psychiatrists evaluating patients already prescribed GLP-1s by other providers, indicating the competency gap persists at the protocol level despite conceptual recognition.
+
+## Extending Evidence
+
+**Source:** Dr. Will Sauvé, Osmind CMO
+
+Osmind CMO Dr. Sauvé frames competency gap as existential for psychiatry: 'If our field of psychiatry does not get a hundred percent ahead of how this GLP thing works, then we're going to be left behind.' Identifies specific gap: psychiatrists managing GLP-1-prescribed patients without understanding central mechanisms, dosing nuances, or psychiatric side effects.

domains/health/glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation.md

@@ -150,3 +150,10 @@ GLP-1 receptors in VTA suppress dopamine signaling through GABA neurons, functio
 **Source:** Parkinson's meta-analysis (5 studies, August 2025), NeurologyLive repositioning article May 2026
 
 Parkinson's motor function improvement across 5 Phase 2 studies provides additional evidence for GLP-1's dopaminergic circuit effects. Parkinson's involves substantia nigra dopaminergic degeneration—the same circuits GLP-1 modulates in SUD. This extends the dopamine modulation mechanism beyond addiction to motor control, strengthening the circuit-specificity hypothesis.
+
+
+## Extending Evidence
+
+**Source:** EVOKE/EVOKE+ trials, Lancet 2026
+
+EVOKE failure in Alzheimer's disease with confirmed pathology defines the boundary condition for GLP-1 CNS efficacy: the drug works through reward/motivation circuits (VTA, NAcc, dopaminergic systems) for SUD and depression, but cannot modify molecular neurodegeneration cascades (amyloid/tau pathology) in established Alzheimer's disease. This mechanistic specificity strengthens the dopaminergic pathway argument by showing what GLP-1 CANNOT do.

domains/health/semaglutide-fails-alzheimers-progression-despite-biomarker-effects-distinguishing-metabolic-prevention-from-neurodegeneration-treatment.md

@@ -0,0 +1,19 @@
+---
+type: claim
+domain: health
+description: "EVOKE/EVOKE+ Phase 3 trials show zero clinical benefit in confirmed AD patients despite 10% p-tau181 reduction, separating GLP-1's metabolic prevention pathway from inability to treat established amyloid/tau pathology"
+confidence: proven
+source: Novo Nordisk EVOKE/EVOKE+ trials, Lancet 2026, AD/PD 2026 conference
+created: 2026-05-07
+title: Semaglutide fails to slow Alzheimer's disease progression despite biomarker effects distinguishing metabolic risk reduction from disease-modifying potential in established neurodegeneration
+agent: vida
+sourced_from: health/2026-05-07-lancet-evoke-semaglutide-alzheimers-failure.md
+scope: causal
+sourcer: Novo Nordisk / EVOKE trial investigators
+supports: ["glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "AI compresses drug discovery timelines by 30-40 percent but has not yet improved the 90 percent clinical failure rate that determines industry economics"]
+related: ["glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "semaglutide-reduces-depression-worsening-44-percent-in-diagnosed-patients-through-glp1r-psychiatric-mechanism"]
+---
+
+# Semaglutide fails to slow Alzheimer's disease progression despite biomarker effects distinguishing metabolic risk reduction from disease-modifying potential in established neurodegeneration
+
+The EVOKE and EVOKE+ Phase 3 trials enrolled 3,800 patients with confirmed Alzheimer's pathology and mild symptomatic disease, randomized to oral semaglutide 14mg vs placebo for 104 weeks. Both trials showed NO DIFFERENCE in primary endpoint (CDR-SB change) or secondary endpoint (ADCS-ADL-MCI). Critically, CSF p-tau181 was reduced by ~10% at week 78 (statistically significant), yet this biomarker improvement produced zero clinical benefit. This disconnection is mechanistically informative: it demonstrates GLP-1 is doing SOMETHING at the molecular level (likely anti-inflammatory), but that mechanism is insufficient to overcome established Alzheimer's pathology. The trial design eliminated the confound present in real-world observational studies where GLP-1 users have metabolic disease—EVOKE enrolled patients with confirmed AD pathology and no metabolic indication. When the metabolic confound was removed, the dementia prevention signal disappeared entirely. This definitively separates two previously conflated claims: (1) GLP-1 prevents dementia in metabolically vulnerable populations through METABOLIC RISK REDUCTION, and (2) GLP-1 treats established Alzheimer's disease through direct modification of neurodegenerative pathology. The answer to (2) is now definitively NO. Novo Nordisk cancelled the planned 1-year extension of both trials following these results. The finding strengthens the mechanistic specificity argument around GLP-1 CNS effects: the drug works through reward/motivation circuits (VTA, NAcc, dopaminergic systems) for SUD and depression, but cannot modify molecular neurodegeneration cascades in established Alzheimer's disease.

domains/health/semaglutide-produces-large-effect-aud-reduction-through-vta-dopamine-suppression.md

@@ -59,3 +59,10 @@ Semaglutide showed most consistent effects across 14 studies in meta-analysis of
 **Source:** Gill et al., JAMA Psychiatry 2026
 
 MDD trial provides complementary evidence of GLP-1 reward circuit engagement but with opposite therapeutic direction—AUD benefits from dopamine suppression (reducing pathological reward), MDD benefits from effort-cost reduction (increasing motivation for reward pursuit). Both operate through same anatomical substrate (VTA/mesolimbic pathway) but different functional mechanisms.
+
+
+## Supporting Evidence
+
+**Source:** Osmind synthesis of Hendershot, Lilly trials, All of Us
+
+Hendershot trial (JAMA Psychiatry 2025) in 48 adults with AUD showed semaglutide effect sizes exceeding naltrexone or acamprosate. Eli Lilly brenipatide Phase 3 (RENEW-ALC) enrolling 2,200 patients with moderate-to-severe AUD. All of Us observational (March 2026): GLP-1 exposure associated with 75% lower odds of any SUD.

domains/health/semaglutide-reduces-depression-worsening-44-percent-in-diagnosed-patients-through-glp1r-psychiatric-mechanism.md

@@ -45,3 +45,10 @@ Within-individual design in Swedish cohort (n=95,490) confirms 44% reduction in
 **Source:** JAMA Psychiatry RCT April 2026, Vida synthesis
 
 JAMA Psychiatry RCT (April 2026) showed GLP-1 improves MDD motivation/avolition specifically through effort discounting measures. This extends the depression mechanism from general 'worsening prevention' to specific improvement in motivation—a reward circuit function consistent with VTA/nucleus accumbens GLP-1R distribution.
+
+
+## Extending Evidence
+
+**Source:** EVOKE/EVOKE+ trials, Lancet 2026
+
+EVOKE failure demonstrates GLP-1 psychiatric effects operate through reward/behavioral circuits rather than by modifying neurodegenerative pathology. The drug's efficacy in depression (44% reduction in worsening) combined with failure in Alzheimer's disease suggests the relevant mechanism is dopaminergic/motivational, not neuroprotective against molecular degeneration.

inbox/archive/health/2026-05-07-lancet-evoke-semaglutide-alzheimers-failure.md

@@ -7,10 +7,13 @@ date: 2026-03-19
 domain: health
 secondary_domains: []
 format: article
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-05-07
 priority: high
 tags: [glp-1, semaglutide, alzheimers, neurodegeneration, EVOKE, clinical-trial-failure, CNS-specificity]
 intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content

inbox/archive/health/2026-05-07-osmind-glp1-psychiatric-drugs-competency.md

@@ -7,10 +7,13 @@ date: 2026-03-17
 domain: health
 secondary_domains: []
 format: article
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-05-07
 priority: high
 tags: [glp-1, psychiatry, competency-gap, anhedonia, addiction, dosing]
 intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content